{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:35:50Z","timestamp":1791646550141,"version":"4.3.4"},"reference-count":136,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T00:00:00Z","timestamp":1746403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T00:00:00Z","timestamp":1746403200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis (MDA5-DM) is a rare systemic autoimmune disease characterized by a clinically amyopathic presentation and a high-risk association with rapidly progressive interstitial lung disease. Although frequently fatal, the underlying mechanisms remain incompletely understood. This review provides a comprehensive summary of recent advances in research on MDA5-DM, aiming to deepen our understanding of its pathogenic mechanisms and to accelerate future basic research that will contribute to the development of novel therapeutic strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>Recent advancements have shed light on various aspects of this disease, including genetic and environmental factors contributing to disease susceptibility and the immunopathological processes and cytokine networks. Furthermore, significant progress has been made in understanding the pathogenicity, epitope recognition, and production mechanisms of anti-MDA5 antibodies, which have long been subjects of debate. On the therapeutic front, in addition to the conventional triple-combination regimen, emerging efficacy of JAK inhibitors and rituximab has been recognized. The development of biologics targeting lymphocytes offers additional hope for advancing therapeutic options.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Advancing our understanding of the latest pathophysiological mechanisms of MDA5-DM is expected to pave the way for the development of safer and more effective therapeutic strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11926-025-01188-7","type":"journal-article","created":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T07:16:35Z","timestamp":1746429395000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Anti- Melanoma Differentiation-Associated Gene 5 Antibody Positive Dermatomyositis: Recent Progress in Pathophysiology and Treatment"],"prefix":"10.1007","volume":"27","author":[{"given":"Tsuneyasu","family":"Yoshida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,5]]},"reference":[{"issue":"8","key":"1188_CR1","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1177\/0961203316651748","volume":"25","author":"R Nakashima","year":"2016","unstructured":"Nakashima R, Hosono Y, Mimori T. Clinical significance and new detection system of autoantibodies in myositis with interstitial lung disease. Lupus. 2016;25(8):925\u201333.","journal-title":"Lupus"},{"issue":"5","key":"1188_CR2","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1001\/jamadermatol.2024.0507","volume":"160","author":"RR Lin","year":"2024","unstructured":"Lin RR, Warp PV, Maderal AD, Elman SA. Assessing time of onset for interstitial lung disease in Anti-MDA5 Antibody-Positive dermatomyositis. JAMA Dermatol. 2024;160(5):575\u20137.","journal-title":"JAMA Dermatol"},{"key":"1188_CR3","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jaut.2019.04.001","volume":"101","author":"Z Betteridge","year":"2019","unstructured":"Betteridge Z, Tansley S, Shaddick G, Chinoy H, Cooper RG, New RP, et al. Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients. J Autoimmun. 2019;101:48\u201355.","journal-title":"J Autoimmun"},{"key":"1188_CR4","doi-asserted-by":"publisher","first-page":"773352","DOI":"10.3389\/fimmu.2021.773352","volume":"12","author":"A Nombel","year":"2021","unstructured":"Nombel A, Fabien N, Coutant F. Dermatomyositis with Anti-MDA5 antibodies: bioclinical features, pathogenesis and emerging therapies. Front Immunol. 2021;12:773352.","journal-title":"Front Immunol"},{"issue":"3","key":"1188_CR5","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1093\/rheumatology\/kep375","volume":"49","author":"R Nakashima","year":"2010","unstructured":"Nakashima R, Imura Y, Kobayashi S, Yukawa N, Yoshifuji H, Nojima T, et al. The RIG-I-like receptor IFIH1\/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology (Oxford). 2010;49(3):433\u201340.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"1188_CR6","doi-asserted-by":"publisher","first-page":"R214","DOI":"10.1186\/ar3547","volume":"13","author":"Y Muro","year":"2011","unstructured":"Muro Y, Sugiura K, Hoshino K, Akiyama M, Tamakoshi K. Epidemiologic study of clinically amyopathic dermatomyositis and anti-melanoma differentiation-associated gene 5 antibodies in central Japan. Arthritis Res Ther. 2011;13(6):R214.","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"1188_CR7","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1093\/rheumatology\/ker518","volume":"51","author":"T Koga","year":"2012","unstructured":"Koga T, Fujikawa K, Horai Y, Okada A, Kawashiri SY, Iwamoto N, et al. The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Rheumatology (Oxford). 2012;51(7):1278\u201384.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"1188_CR8","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1002\/art.21023","volume":"52","author":"S Sato","year":"2005","unstructured":"Sato S, Hirakata M, Kuwana M, Suwa A, Inada S, Mimori T, et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum. 2005;52(5):1571\u20136.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"1188_CR9","first-page":"891","volume":"32","author":"A Ceribelli","year":"2014","unstructured":"Ceribelli A, Fredi M, Taraborelli M, Cavazzana I, Tincani A, Selmi C, et al. Prevalence and clinical significance of anti-MDA5 antibodies in European patients with polymyositis\/dermatomyositis. Clin Exp Rheumatol. 2014;32(6):891\u20137.","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"1188_CR10","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1080\/03009740802687455","volume":"38","author":"K Fujikawa","year":"2009","unstructured":"Fujikawa K, Kawakami A, Kaji K, Fujimoto M, Kawashiri S, Iwamoto N, et al. Association of distinct clinical subsets with myositis-specific autoantibodies towards anti-155\/140-kDa polypeptides, anti-140-kDa polypeptides, and anti-aminoacyl tRNA synthetases in Japanese patients with dermatomyositis: a single-centre, cross-sectional study. Scand J Rheumatol. 2009;38(4):263\u20137.","journal-title":"Scand J Rheumatol"},{"issue":"1","key":"1188_CR11","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jaad.2010.09.016","volume":"65","author":"D Fiorentino","year":"2011","unstructured":"Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol. 2011;65(1):25\u201334.","journal-title":"J Am Acad Dermatol"},{"key":"1188_CR12","doi-asserted-by":"publisher","first-page":"290797","DOI":"10.1155\/2014\/290797","volume":"2014","author":"M Labrador-Horrillo","year":"2014","unstructured":"Labrador-Horrillo M, Martinez MA, Selva-O\u2019Callaghan A, Trallero-Araguas E, Balada E, Vilardell-Tarres M, et al. Anti-MDA5 antibodies in a large mediterranean population of adults with dermatomyositis. J Immunol Res. 2014;2014:290797.","journal-title":"J Immunol Res"},{"issue":"11","key":"1188_CR13","doi-asserted-by":"publisher","first-page":"3736","DOI":"10.1002\/art.34657","volume":"64","author":"T Gono","year":"2012","unstructured":"Gono T, Kawaguchi Y, Kuwana M, Sugiura T, Furuya T, Takagi K, et al. Brief report: association of HLA-DRB1*0101\/*0405 with susceptibility to anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis in the Japanese population. Arthritis Rheum. 2012;64(11):3736\u201340.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"1188_CR14","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1136\/annrheumdis-2019-215046","volume":"78","author":"S Rothwell","year":"2019","unstructured":"Rothwell S, Chinoy H, Lamb JA, Miller FW, Rider LG, Wedderburn LR, et al. Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups. Ann Rheum Dis. 2019;78(7):996\u20131002.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1188_CR15","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1136\/annrheumdis-2017-212149","volume":"77","author":"Y Kochi","year":"2018","unstructured":"Kochi Y, Kamatani Y, Kondo Y, Suzuki A, Kawakami E, Hiwa R, et al. Splicing variant of WDFY4 augments MDA5 signalling and the risk of clinically amyopathic dermatomyositis. Ann Rheum Dis. 2018;77(4):602\u201311.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1188_CR16","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1093\/rheumatology\/kead006","volume":"62","author":"L Guo","year":"2023","unstructured":"Guo L, Zhang X, Pu W, Zhao J, Wang K, Zhang D, et al. WDFY4 polymorphisms in Chinese patients with anti-MDA5 dermatomyositis is associated with rapid progressive interstitial lung disease. Rheumatology (Oxford). 2023;62(6):2320\u20134.","journal-title":"Rheumatology (Oxford)"},{"issue":"6415","key":"1188_CR17","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1126\/science.aat5030","volume":"362","author":"DJ Theisen","year":"2018","unstructured":"Theisen DJ, Davidson JT, Brise\u00f1o CG, Gargaro M, Lauron EJ, Wang Q, et al. WDFY4 is required for cross-presentation in response to viral and tumor antigens. Science. 2018;362(6415):694\u20139.","journal-title":"Science"},{"key":"1188_CR18","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.molimm.2021.08.022","volume":"139","author":"Y Li","year":"2021","unstructured":"Li Y, Li J, Yuan Q, Bian X, Long F, Duan R, et al. Deficiency in WDFY4 reduces the number of CD8\u2009+\u2009T cells via reactive oxygen species-induced apoptosis. Mol Immunol. 2021;139:131\u20138.","journal-title":"Mol Immunol"},{"issue":"8","key":"1188_CR19","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1002\/acr.21985","volume":"65","author":"Z Chen","year":"2013","unstructured":"Chen Z, Cao M, Plana MN, Liang J, Cai H, Kuwana M, et al. Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis. Arthritis Care Res (Hoboken). 2013;65(8):1316\u201324.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"1188_CR20","doi-asserted-by":"publisher","first-page":"e001202","DOI":"10.1136\/rmdopen-2020-001202","volume":"6","author":"N Nishina","year":"2020","unstructured":"Nishina N, Sato S, Masui K, Gono T, Kuwana M. Seasonal and residential clustering at disease onset of anti-MDA5-associated interstitial lung disease. RMD Open. 2020;6(2):e001202.","journal-title":"RMD Open"},{"issue":"4","key":"1188_CR21","doi-asserted-by":"publisher","first-page":"102788","DOI":"10.1016\/j.autrev.2021.102788","volume":"20","author":"S Toquet","year":"2021","unstructured":"Toquet S, Granger B, Uzunhan Y, Mariampillai K, Nunes H, Benveniste O, et al. The seasonality of dermatomyositis associated with anti-MDA5 antibody: an argument for a respiratory viral trigger. Autoimmun Rev. 2021;20(4):102788.","journal-title":"Autoimmun Rev"},{"key":"1188_CR22","doi-asserted-by":"publisher","first-page":"106966","DOI":"10.1016\/j.imlet.2024.106966","volume":"272","author":"B Palterer","year":"2024","unstructured":"Palterer B, Mazzoni A, Infantino M, Semeraro R, Manfredi M, Pesce G, et al. Seasonal patterns of myositis-specific and myositis-associated autoantibodies in Italy: seasonal patterns of myositis autoantibodies. Immunol Lett. 2024;272:106966.","journal-title":"Immunol Lett"},{"key":"1188_CR23","doi-asserted-by":"publisher","first-page":"837024","DOI":"10.3389\/fmed.2022.837024","volume":"9","author":"H So","year":"2022","unstructured":"So H, So J, Lam TTO, Wong VTL, Ho R, Li WL, et al. Seasonal effect on disease onset and presentation in Anti-MDA5 positive dermatomyositis. Front Med (Lausanne). 2022;9:837024.","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"1188_CR24","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1073\/pnas.022637199","volume":"99","author":"Dchul Kang","year":"2002","unstructured":"Kang Dchul, Gopalkrishnan RV, Wu Q, Jankowsky E, Pyle AM, Fisher PB. mda-5: an interferon-inducible putative RNA helicase with double-stranded RNA-dependent ATPase activity and melanoma growth-suppressive properties. Proc Natl Acad Sci U S A. 2002;99(2):637\u201342.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"1188_CR25","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1038\/sj.onc.1207300","volume":"23","author":"DC Kang","year":"2004","unstructured":"Kang DC, Gopalkrishnan RV, Lin L, Randolph A, Valerie K, Pestka S, et al. Expression analysis and genomic characterization of human melanoma differentiation associated gene-5, mda-5: a novel type I interferon-responsive apoptosis-inducing gene. Oncogene. 2004;23(9):1789\u2013800.","journal-title":"Oncogene"},{"issue":"5","key":"1188_CR26","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/j.jaad.2010.08.004","volume":"64","author":"S Zahn","year":"2011","unstructured":"Zahn S, Barchet W, Rehk\u00e4mper C, Hornung T, Bieber T, T\u00fcting T, et al. Enhanced skin expression of melanoma differentiation-associated gene 5 (MDA5) in dermatomyositis and related autoimmune diseases. J Am Acad Dermatol. 2011;64(5):988\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1188_CR27","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1093\/rheumatology\/keab371","volume":"61","author":"T Gono","year":"2022","unstructured":"Gono T, Okazaki Y, Kuwana M. Antiviral Proinflammatory phenotype of monocytes in anti-MDA5 antibody-associated interstitial lung disease. Rheumatology (Oxford). 2022;61(2):806\u201314.","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"1188_CR28","doi-asserted-by":"publisher","first-page":"3724","DOI":"10.1093\/rheumatology\/kead117","volume":"62","author":"Y Liu","year":"2023","unstructured":"Liu Y, Feng S, Liu X, Tang Y, Li X, Luo C, et al. IFN-beta and EIF2AK2 are potential biomarkers for interstitial lung disease in anti-MDA5 positive dermatomyositis. Rheumatology (Oxford). 2023;62(11):3724\u201331.","journal-title":"Rheumatology (Oxford)"},{"key":"1188_CR29","doi-asserted-by":"crossref","unstructured":"Jayaraman S, Tiniakou E, Morgenlander WR, Na M, Christopher-Stine L, Larman HB. Comprehensive enteroviral serology links infection and Anti-Melanoma Differentiation-Associated protein 5 dermatomyositis. ACR Open Rheumatol; 2024.","DOI":"10.1002\/acr2.11752"},{"issue":"12","key":"1188_CR30","doi-asserted-by":"publisher","first-page":"103686","DOI":"10.1016\/j.autrev.2024.103686","volume":"23","author":"C Castellini","year":"2024","unstructured":"Castellini C, Scotti C, Navarini L, Fu Q, Qian J, Giacomelli R, et al. The evaluation of type I interferon score in dermatomyositis, a systematic review and a meta-analysis. Autoimmun Rev. 2024;23(12):103686.","journal-title":"Autoimmun Rev"},{"issue":"5","key":"1188_CR31","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1111\/bjd.16917","volume":"180","author":"SH Zhang","year":"2019","unstructured":"Zhang SH, Zhao Y, Xie QB, Jiang Y, Wu YK, Yan B. Aberrant activation of the type I interferon system May contribute to the pathogenesis of anti-melanoma differentiation-associated gene 5 dermatomyositis. Br J Dermatol. 2019;180(5):1090\u20138.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1188_CR32","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.jid.2019.10.020","volume":"140","author":"C Cassius","year":"2020","unstructured":"Cassius C, Amode R, Delord M, Battistella M, Poirot J, How-Kit A, et al. MDA5\u2009+\u2009Dermatomyositis is associated with stronger skin type I interferon transcriptomic signature with upregulation of IFN-\u03ba transcript. J Invest Dermatol. 2020;140(6):1276\u2013e12797.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"1188_CR33","doi-asserted-by":"publisher","first-page":"6458","DOI":"10.1038\/s41467-022-34145-4","volume":"13","author":"Y Ye","year":"2022","unstructured":"Ye Y, Chen Z, Jiang S, Jia F, Li T, Lu X, et al. Single-cell profiling reveals distinct adaptive immune hallmarks in MDA5\u2009+\u2009dermatomyositis with therapeutic implications. Nat Commun. 2022;13(1):6458.","journal-title":"Nat Commun"},{"issue":"5","key":"1188_CR34","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1093\/rheumatology\/key386","volume":"58","author":"N Ono","year":"2019","unstructured":"Ono N, Kai K, Maruyama A, Sakai M, Sadanaga Y, Koarada S, et al. The relationship between type 1 IFN and vasculopathy in anti-MDA5 antibody-positive dermatomyositis patients. Rheumatology (Oxford). 2019;58(5):786\u201391.","journal-title":"Rheumatology (Oxford)"},{"key":"1188_CR35","doi-asserted-by":"publisher","first-page":"1151695","DOI":"10.3389\/fimmu.2023.1151695","volume":"14","author":"J Qian","year":"2023","unstructured":"Qian J, Li R, Chen Z, Cao Z, Lu L, Fu Q. Type I interferon score is associated with the severity and poor prognosis in anti-MDA5 antibody-positive dermatomyositis patients. Front Immunol. 2023;14:1151695.","journal-title":"Front Immunol"},{"issue":"2","key":"1188_CR36","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.immuni.2013.12.014","volume":"40","author":"M Funabiki","year":"2014","unstructured":"Funabiki M, Kato H, Miyachi Y, Toki H, Motegi H, Inoue M, et al. Autoimmune disorders associated with gain of function of the intracellular sensor MDA5. Immunity. 2014;40(2):199\u2013212.","journal-title":"Immunity"},{"issue":"11","key":"1188_CR37","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1093\/rheumatology\/keaa123","volume":"59","author":"M Shirakashi","year":"2020","unstructured":"Shirakashi M, Nakashima R, Tsuji H, Tanizawa K, Handa T, Hosono Y, et al. Efficacy of plasma exchange in anti-MDA5-positive dermatomyositis with interstitial lung disease under combined immunosuppressive treatment. Rheumatology (Oxford). 2020;59(11):3284\u201392.","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"1188_CR38","doi-asserted-by":"publisher","first-page":"935","DOI":"10.3899\/jrheum.180825","volume":"46","author":"T Fujisawa","year":"2019","unstructured":"Fujisawa T, Hozumi H, Yasui H, Suzuki Y, Karayama M, Furuhashi K, et al. Clinical significance of serum Chitotriosidase level in Anti-MDA5 Antibody-positive Dermatomyositis-associated interstitial lung disease. J Rheumatol. 2019;46(8):935\u201342.","journal-title":"J Rheumatol"},{"issue":"1","key":"1188_CR39","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13075-016-1214-8","volume":"19","author":"Y Enomoto","year":"2017","unstructured":"Enomoto Y, Suzuki Y, Hozumi H, Mori K, Kono M, Karayama M, et al. Clinical significance of soluble CD163 in polymyositis-related or dermatomyositis-related interstitial lung disease. Arthritis Res Ther. 2017;19(1):9.","journal-title":"Arthritis Res Ther"},{"key":"1188_CR40","doi-asserted-by":"publisher","first-page":"628128","DOI":"10.3389\/fcell.2021.628128","volume":"9","author":"L Liang","year":"2021","unstructured":"Liang L, Zhang YM, Shen YW, Song AP, Li WL, Ye LF, et al. Aberrantly expressed Galectin-9 is involved in the Immunopathogenesis of Anti-MDA5-Positive Dermatomyositis-Associated interstitial lung disease. Front Cell Dev Biol. 2021;9:628128.","journal-title":"Front Cell Dev Biol"},{"issue":"2","key":"1188_CR41","first-page":"275","volume":"41","author":"A Kokuzawa","year":"2023","unstructured":"Kokuzawa A, Nakamura J, Kamata Y, Sato K. Potential role of type I interferon\/IP-10 axis in the pathogenesis of anti-MDA5 antibody-positive dermatomyositis. Clin Exp Rheumatol. 2023;41(2):275\u201384.","journal-title":"Clin Exp Rheumatol"},{"key":"1188_CR42","doi-asserted-by":"crossref","unstructured":"Kuzumi A, Fukasawa T, Yamashita T, Matsuda KM, Kotani H, Yoshizaki-Ogawa A et al. Serum interleukin-34 levels in dermatomyositis: a potential biomarker for anti-MDA5-antibody-associated interstitial lung disease. Rheumatology (Oxford). 2024;keae313.","DOI":"10.1093\/rheumatology\/keae313"},{"issue":"12","key":"1188_CR43","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1093\/rheumatology\/keu258","volume":"53","author":"T Gono","year":"2014","unstructured":"Gono T, Kaneko H, Kawaguchi Y, Hanaoka M, Kataoka S, Kuwana M, et al. Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease. Rheumatology (Oxford). 2014;53(12):2196\u2013203.","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"1188_CR44","doi-asserted-by":"publisher","first-page":"103420","DOI":"10.1016\/j.autrev.2023.103420","volume":"22","author":"J Thuner","year":"2023","unstructured":"Thuner J, Coutant F. IFN-\u03b3: an overlooked cytokine in dermatomyositis with anti-MDA5 antibodies. Autoimmun Rev. 2023;22(10):103420.","journal-title":"Autoimmun Rev"},{"issue":"5","key":"1188_CR45","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1002\/art.42785","volume":"76","author":"A Fukada","year":"2024","unstructured":"Fukada A, Fujisawa T, Hozumi H, Koda K, Akamatsu T, Oyama Y, et al. Prognostic role of Interferon-\u03bb3 in Anti-Melanoma Differentiation-Associated gene 5-Positive Dermatomyositis-Associated interstitial lung disease. Arthritis Rheumatol. 2024;76(5):796\u2013805.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"1188_CR46","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/s13075-018-1737-2","volume":"20","author":"Y Ishikawa","year":"2018","unstructured":"Ishikawa Y, Iwata S, Hanami K, Nawata A, Zhang M, Yamagata K, et al. Relevance of interferon-gamma in pathogenesis of life-threatening rapidly progressive interstitial lung disease in patients with dermatomyositis. Arthritis Res Ther. 2018;20(1):240.","journal-title":"Arthritis Res Ther"},{"key":"1188_CR47","doi-asserted-by":"publisher","first-page":"102831","DOI":"10.1016\/j.jaut.2022.102831","volume":"130","author":"F Coutant","year":"2022","unstructured":"Coutant F, Bachet R, Pin JJ, Alonzo M, Miossec P. Monoclonal antibodies from B cells of patients with anti-MDA5 antibody-positive dermatomyositis directly stimulate interferon gamma production. J Autoimmun. 2022;130:102831.","journal-title":"J Autoimmun"},{"issue":"1","key":"1188_CR48","doi-asserted-by":"publisher","first-page":"16833","DOI":"10.1038\/s41598-017-17007-8","volume":"7","author":"Y Ishida","year":"2017","unstructured":"Ishida Y, Kimura A, Nosaka M, Kuninaka Y, Hemmi H, Sasaki I, et al. Essential involvement of the CX3CL1-CX3CR1 axis in bleomycin-induced pulmonary fibrosis via regulation of fibrocyte and M2 macrophage migration. Sci Rep. 2017;7(1):16833.","journal-title":"Sci Rep"},{"issue":"2","key":"1188_CR49","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.trsl.2010.11.007","volume":"157","author":"T Isozaki","year":"2011","unstructured":"Isozaki T, Otsuka K, Sato M, Takahashi R, Wakabayashi K, Yajima N, et al. Synergistic induction of CX3CL1 by interleukin-1\u03b2 and interferon-\u03b3 in human lung fibroblasts: involvement of signal transducer and activator of transcription 1 signaling pathways. Transl Res. 2011;157(2):64\u201370.","journal-title":"Transl Res"},{"issue":"16","key":"1188_CR50","doi-asserted-by":"publisher","first-page":"e139558","DOI":"10.1172\/jci.insight.139558","volume":"5","author":"LC Tsoi","year":"2020","unstructured":"Tsoi LC, Gharaee-Kermani M, Berthier CC, Nault T, Hile GA, Estadt SN, et al. IL18-containing 5-gene signature distinguishes histologically identical dermatomyositis and lupus erythematosus skin lesions. JCI Insight. 2020;5(16):e139558.","journal-title":"JCI Insight"},{"key":"1188_CR51","doi-asserted-by":"crossref","unstructured":"Wen J, Zhou M, Lai Y, Zhuang L, Shi J, Lin Z et al. Serum level of IFN-\u03bb is elevated in idiopathic inflammatory myopathies. Clin Rheumatol. 2024.","DOI":"10.1007\/s10067-024-07227-5"},{"issue":"12","key":"1188_CR52","doi-asserted-by":"publisher","first-page":"3886","DOI":"10.1093\/rheumatology\/keaa266","volume":"59","author":"W Huang","year":"2020","unstructured":"Huang W, Ren F, Luo L, Zhou J, Huang D, Pan Z, et al. The characteristics of lymphocytes in patients positive for anti-MDA5 antibodies in interstitial lung disease. Rheumatology (Oxford). 2020;59(12):3886\u201391.","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"1188_CR53","doi-asserted-by":"publisher","first-page":"3909","DOI":"10.1007\/s00296-011-2323-y","volume":"32","author":"F Chen","year":"2012","unstructured":"Chen F, Wang D, Shu X, Nakashima R, Wang G. Anti-MDA5 antibody is associated with A\/SIP and decreased T cells in peripheral blood and predicts poor prognosis of ILD in Chinese patients with dermatomyositis. Rheumatol Int. 2012;32(12):3909\u201315.","journal-title":"Rheumatol Int"},{"issue":"4","key":"1188_CR54","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1111\/joim.13607","volume":"293","author":"Q Jin","year":"2023","unstructured":"Jin Q, Fu L, Yang H, Chen X, Lin S, Huang Z, et al. Peripheral lymphocyte count defines the clinical phenotypes and prognosis in patients with anti-MDA5-positive dermatomyositis. J Intern Med. 2023;293(4):494\u2013507.","journal-title":"J Intern Med"},{"key":"1188_CR55","doi-asserted-by":"crossref","unstructured":"Tian Y, He P, Ren L, Xin H, Xi B, Zou R et al. Dynamic change of lymphocytes associated with short-term prognosis in anti-MDA5-positive dermatomyositis with interstitial lung disease: a multicenter retrospective study. Clin Rheumatol. 2024.","DOI":"10.1007\/s10067-024-07110-3"},{"issue":"2","key":"1188_CR56","doi-asserted-by":"publisher","first-page":"e70226","DOI":"10.1002\/ctm2.70226","volume":"15","author":"J Shi","year":"2025","unstructured":"Shi J, Pei X, Peng J, Wu C, Lv Y, Wang X, et al. Monocyte-macrophage dynamics as key in disparate lung and peripheral immune responses in severe anti-melanoma differentiation-associated gene 5-positive dermatomyositis-related interstitial lung disease. Clin Transl Med. 2025;15(2):e70226.","journal-title":"Clin Transl Med"},{"issue":"1","key":"1188_CR57","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13075-019-1905-z","volume":"21","author":"L Zhang","year":"2019","unstructured":"Zhang L, Xia Q, Li W, Peng Q, Yang H, Lu X, et al. The RIG-I pathway is involved in peripheral T cell lymphopenia in patients with dermatomyositis. Arthritis Res Ther. 2019;21(1):131.","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"1188_CR58","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1111\/1346-8138.15117","volume":"46","author":"T Matsushita","year":"2019","unstructured":"Matsushita T, Kobayashi T, Kano M, Hamaguchi Y, Takehara K. Elevated serum B-cell activating factor levels in patients with dermatomyositis: association with interstitial lung disease. J Dermatol. 2019;46(12):1190\u20136.","journal-title":"J Dermatol"},{"issue":"1","key":"1188_CR59","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s13023-024-03153-6","volume":"19","author":"Y Shi","year":"2024","unstructured":"Shi Y, You H, Liu C, Qiu Y, Lv C, Zhu Y, et al. Elevated serum B-cell activator factor levels predict rapid progressive interstitial lung disease in anti-melanoma differentiation associated protein 5 antibody positive dermatomyositis. Orphanet J Rare Dis. 2024;19(1):170.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"1188_CR60","doi-asserted-by":"publisher","first-page":"260","DOI":"10.55563\/clinexprheumatol\/ohsmuj","volume":"40","author":"Y Wang","year":"2022","unstructured":"Wang Y, Zhu L, Ju B, Luo J, Li Q, Lv X, et al. Alterations of peripheral blood B cell subsets in Chinese patients with adult idiopathic inflammatory myopathies. Clin Exp Rheumatol. 2022;40(2):260\u20136.","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"1188_CR61","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/acr2.11521","volume":"5","author":"Y Sugimori","year":"2023","unstructured":"Sugimori Y, Iwasaki Y, Takeshima Y, Okubo M, Kobayashi S, Hatano H, et al. Transcriptome profiling of immune cell types in peripheral blood reveals common and specific pathways involved in the pathogenesis of Myositis-Specific Antibody-Positive inflammatory myopathies. ACR Open Rheumatol. 2023;5(2):93\u2013102.","journal-title":"ACR Open Rheumatol"},{"issue":"2","key":"1188_CR62","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3899\/jrheum.220139","volume":"50","author":"C Lv","year":"2023","unstructured":"Lv C, You H, Xu L, Wang L, Yuan F, Li J, et al. Coexistence of Anti-Ro52 antibodies in Anti-MDA5 Antibody-Positive dermatomyositis is highly associated with rapidly progressive interstitial lung disease and mortality risk. J Rheumatol. 2023;50(2):219\u201326.","journal-title":"J Rheumatol"},{"issue":"7","key":"1188_CR63","doi-asserted-by":"publisher","first-page":"3343","DOI":"10.1093\/rheumatology\/keaa786","volume":"60","author":"A Xu","year":"2021","unstructured":"Xu A, Ye Y, Fu Q, Lian X, Chen S, Guo Q, et al. Prognostic values of anti-Ro52 antibodies in anti-MDA5-positive clinically amyopathic dermatomyositis associated with interstitial lung disease. Rheumatology (Oxford). 2021;60(7):3343\u201351.","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"1188_CR64","doi-asserted-by":"publisher","first-page":"4570","DOI":"10.1093\/rheumatology\/keac090","volume":"61","author":"X Gui","year":"2022","unstructured":"Gui X, Shenyun S, Ding H, Wang R, Tong J, Yu M, et al. Anti-Ro52 antibodies are associated with the prognosis of adult idiopathic inflammatory myopathy-associated interstitial lung disease. Rheumatology (Oxford). 2022;61(11):4570\u20138.","journal-title":"Rheumatology (Oxford)"},{"key":"1188_CR65","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jaut.2016.11.006","volume":"77","author":"Y Hosono","year":"2017","unstructured":"Hosono Y, Nakashima R, Serada S, Murakami K, Imura Y, Yoshifuji H, et al. Splicing factor proline\/glutamine-rich is a novel autoantigen of dermatomyositis and associated with anti-melanoma differentiation-associated gene 5 antibody. J Autoimmun. 2017;77:116\u201322.","journal-title":"J Autoimmun"},{"issue":"3","key":"1188_CR66","doi-asserted-by":"publisher","first-page":"103013","DOI":"10.1016\/j.autrev.2021.103013","volume":"21","author":"P Decker","year":"2022","unstructured":"Decker P, Moulinet T, Pontille F, Cravat M, De Carvalho Bittencourt M, Jaussaud R. An updated review of anti-Ro52 (TRIM21) antibodies impact in connective tissue diseases clinical management. Autoimmun Rev. 2022;21(3):103013.","journal-title":"Autoimmun Rev"},{"issue":"3","key":"1188_CR67","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.4049\/jimmunol.181.3.1780","volume":"181","author":"R Higgs","year":"2008","unstructured":"Higgs R, N\u00ed Gabhann J, Ben Larbi N, Breen EP, Fitzgerald KA, Jefferies CA. The E3 ubiquitin ligase Ro52 negatively regulates IFN-beta production post-pathogen recognition by polyubiquitin-mediated degradation of IRF3. J Immunol. 2008;181(3):1780\u20136.","journal-title":"J Immunol"},{"issue":"7","key":"1188_CR68","doi-asserted-by":"publisher","first-page":"e11776","DOI":"10.1371\/journal.pone.0011776","volume":"5","author":"R Higgs","year":"2010","unstructured":"Higgs R, Lazzari E, Wynne C, N\u00ed Gabhann J, Espinosa A, Wahren-Herlenius M, et al. Self protection from anti-viral responses\u2013Ro52 promotes degradation of the transcription factor IRF7 downstream of the viral Toll-Like receptors. PLoS ONE. 2010;5(7):e11776.","journal-title":"PLoS ONE"},{"issue":"42","key":"1188_CR69","doi-asserted-by":"publisher","first-page":"36478","DOI":"10.1074\/jbc.M111.241786","volume":"286","author":"A Espinosa","year":"2011","unstructured":"Espinosa A, Hennig J, Ambrosi A, Anandapadmanaban M, Abelius MS, Sheng Y, et al. Anti-Ro52 autoantibodies from patients with Sj\u00f6gren\u2019s syndrome inhibit the Ro52 E3 ligase activity by blocking the E3\/E2 interface. J Biol Chem. 2011;286(42):36478\u201391.","journal-title":"J Biol Chem"},{"issue":"3","key":"1188_CR70","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1002\/acn3.51311","volume":"8","author":"Y Jiang","year":"2021","unstructured":"Jiang Y, Liu Y, Zhao Y, Zheng Y, Yu M, Deng J, et al. Mitochondrial morphology and MAVS-IFN1 signaling pathway in muscles of anti-MDA5 dermatomyositis. Ann Clin Transl Neurol. 2021;8(3):677\u201386.","journal-title":"Ann Clin Transl Neurol"},{"key":"1188_CR71","doi-asserted-by":"publisher","first-page":"152483","DOI":"10.1016\/j.semarthrit.2024.152483","volume":"67","author":"C Li","year":"2024","unstructured":"Li C, Han Y, Li X, Zhang H, Yao Z, Zhou J, et al. Soluble CXCL16 is a prognostic biomarker associated with rapidly progressive interstitial lung disease complicated with dermatomyositis. Semin Arthritis Rheum. 2024;67:152483.","journal-title":"Semin Arthritis Rheum"},{"issue":"7","key":"1188_CR72","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1093\/rheumatology\/kes012","volume":"51","author":"T Gono","year":"2012","unstructured":"Gono T, Miyake K, Kawaguchi Y, Kaneko H, Shinozaki M, Yamanaka H. Hyperferritinaemia and macrophage activation in a patient with interstitial lung disease with clinically amyopathic DM. Rheumatology (Oxford). 2012;51(7):1336\u20138.","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"1188_CR73","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1093\/rheumatology\/keaa034","volume":"59","author":"Y Zuo","year":"2020","unstructured":"Zuo Y, Ye L, Liu M, Li S, Liu W, Chen F, et al. Clinical significance of radiological patterns of HRCT and their association with macrophage activation in dermatomyositis. Rheumatology (Oxford). 2020;59(10):2829\u201337.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"1188_CR74","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1093\/rheumatology\/key341","volume":"58","author":"K Wang","year":"2019","unstructured":"Wang K, Zhao J, Chen Z, Li T, Tan X, Zheng Y, et al. CD4\u2009+\u2009CXCR4\u2009+\u2009T cells as a novel prognostic biomarker in patients with idiopathic inflammatory myopathy-associated interstitial lung disease. Rheumatology (Oxford). 2019;58(3):511\u201321.","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"1188_CR75","doi-asserted-by":"publisher","first-page":"5251","DOI":"10.4049\/jimmunol.1500777","volume":"195","author":"TY Brodeur","year":"2015","unstructured":"Brodeur TY, Robidoux TE, Weinstein JS, Craft J, Swain SL, Marshak-Rothstein A. IL-21 promotes pulmonary fibrosis through the induction of profibrotic CD8\u2009+\u2009T cells. J Immunol. 2015;195(11):5251\u201360.","journal-title":"J Immunol"},{"issue":"1","key":"1188_CR76","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s00438-024-02116-7","volume":"299","author":"L Zhu","year":"2024","unstructured":"Zhu L, Xu Y, Wang J, Zhang Y, Zhou J, Wu H. Mesenchymal stem cells-derived exosomes carrying microRNA-30b confer protection against pulmonary fibrosis by downregulating Runx1 via Spred2. Mol Genet Genomics. 2024;299(1):33.","journal-title":"Mol Genet Genomics"},{"issue":"1","key":"1188_CR77","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/rheumatology\/keac234","volume":"62","author":"N Shen","year":"2022","unstructured":"Shen N, Zhou X, Jin X, Lu C, Hu X, Zhang Y, et al. MDA5 expression is associated with TGF-\u03b2-induced fibrosis: potential mechanism of interstitial lung disease in anti-MDA5 dermatomyositis. Rheumatology (Oxford). 2022;62(1):373\u201383.","journal-title":"Rheumatology (Oxford)"},{"key":"1188_CR78","doi-asserted-by":"publisher","first-page":"1249844","DOI":"10.3389\/fimmu.2023.1249844","volume":"14","author":"Y Wang","year":"2023","unstructured":"Wang Y, Jia H, Li W, Liu H, Tu M, Li J, et al. Transcriptomic profiling and longitudinal study reveal the relationship of anti-MDA5 titer and type I IFN signature in MDA5\u2009+\u2009dermatomyositis. Front Immunol. 2023;14:1249844.","journal-title":"Front Immunol"},{"issue":"2","key":"1188_CR79","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/bjd.14882","volume":"176","author":"T Matsushita","year":"2017","unstructured":"Matsushita T, Mizumaki K, Kano M, Yagi N, Tennichi M, Takeuchi A, et al. Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis. Br J Dermatol. 2017;176(2):395\u2013402.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1188_CR80","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1093\/rheumatology\/ker408","volume":"51","author":"Y Muro","year":"2012","unstructured":"Muro Y, Sugiura K, Hoshino K, Akiyama M. Disappearance of anti-MDA-5 autoantibodies in clinically amyopathic DM\/interstitial lung disease during disease remission. Rheumatology (Oxford). 2012;51(5):800\u20134.","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"1188_CR81","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1093\/rheumatology\/kex188","volume":"56","author":"Y Abe","year":"2017","unstructured":"Abe Y, Matsushita M, Tada K, Yamaji K, Takasaki Y, Tamura N. Clinical characteristics and change in the antibody titres of patients with anti-MDA5 antibody-positive inflammatory myositis. Rheumatology (Oxford). 2017;56(9):1492\u20137.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"1188_CR82","doi-asserted-by":"publisher","first-page":"e134189","DOI":"10.1172\/jci.insight.134189","volume":"5","author":"N Seto","year":"2020","unstructured":"Seto N, Torres-Ruiz JJ, Carmona-Rivera C, Pinal-Fernandez I, Pak K, Purmalek MM, et al. Neutrophil dysregulation is pathogenic in idiopathic inflammatory myopathies. JCI Insight. 2020;5(3):e134189.","journal-title":"JCI Insight"},{"key":"1188_CR83","doi-asserted-by":"publisher","first-page":"743704","DOI":"10.3389\/fimmu.2021.743704","volume":"12","author":"K Wang","year":"2021","unstructured":"Wang K, Zhao J, Wu W, Xu W, Sun S, Chen Z, et al. RNA-Containing immune complexes formed by Anti-Melanoma differentiation associated gene 5 autoantibody are potent inducers of IFN-\u03b1. Front Immunol. 2021;12:743704.","journal-title":"Front Immunol"},{"key":"1188_CR84","unstructured":"Pinal-Fernandez I, Mu\u00f1oz-Braceras S, Casal-Dominguez M, Pak K, Torres-Ruiz J, Musai J et al. Pathological autoantibody internalisation in myositis. Ann Rheum Dis. 2024;ard-2024-225773."},{"issue":"1","key":"1188_CR85","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12931-023-02362-0","volume":"24","author":"Y Zaizen","year":"2023","unstructured":"Zaizen Y, Okamoto M, Azuma K, Fukuoka J, Hozumi H, Sakamoto N, et al. Enhanced immune complex formation in the lungs of patients with dermatomyositis. Respir Res. 2023;24(1):86.","journal-title":"Respir Res"},{"issue":"16","key":"1188_CR86","doi-asserted-by":"publisher","first-page":"e2313070121","DOI":"10.1073\/pnas.2313070121","volume":"121","author":"Y Ichimura","year":"2024","unstructured":"Ichimura Y, Konishi R, Shobo M, Tanaka R, Kubota N, Kayama H, et al. Autoimmunity against melanoma differentiation-associated gene 5 induces interstitial lung disease mimicking dermatomyositis in mice. Proc Natl Acad Sci U S A. 2024;121(16):e2313070121.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"1188_CR87","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1093\/rheumatology\/keab268","volume":"61","author":"M Chen","year":"2021","unstructured":"Chen M, Zhao Q, Diao L, Xue K, Ruan Y, Xue F, et al. Distribution of anti-melanoma differentiation associated gene 5 (MDA5) IgG subclasses in MDA5\u2009+\u2009dermatomyositis. Rheumatology (Oxford). 2021;61(1):430\u20139.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"1188_CR88","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/rheumatology\/keac229","volume":"62","author":"YT Xu","year":"2022","unstructured":"Xu YT, Zhang YM, Yang HX, Ye LF, Chen F, Lu X, et al. Evaluation and validation of the prognostic value of anti-MDA5 IgG subclasses in dermatomyositis-associated interstitial lung disease. Rheumatology (Oxford). 2022;62(1):397\u2013406.","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"1188_CR89","doi-asserted-by":"publisher","first-page":"3400","DOI":"10.4049\/jimmunol.2000263","volume":"205","author":"W Hoepel","year":"2020","unstructured":"Hoepel W, Allahverdiyeva S, Harbiye H, de Taeye SW, van der Ham AJ, de Boer L, et al. IgG subclasses shape cytokine responses by human myeloid immune cells through differential metabolic reprogramming. J Immunol. 2020;205(12):3400\u20137.","journal-title":"J Immunol"},{"issue":"5","key":"1188_CR90","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1093\/rheumatology\/kead397","volume":"63","author":"Y Mo","year":"2024","unstructured":"Mo Y, Ye Y, Peng L, Sun X, Zhong X, Wu R. The central helicase domain holds the major conformational epitopes of melanoma differentiation-associated gene 5 autoantibodies. Rheumatology (Oxford). 2024;63(5):1456\u201365.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"1188_CR91","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1093\/rheumatology\/kead400","volume":"63","author":"E Van Gompel","year":"2024","unstructured":"Van Gompel E, Demirdal D, Fernandes-Cerqueira C, Horuluoglu B, Galindo-Feria A, Wigren E, et al. Autoantibodies against the melanoma differentiation-associated protein 5 in patients with dermatomyositis target the helicase domains. Rheumatology (Oxford). 2024;63(5):1466\u201373.","journal-title":"Rheumatology (Oxford)"},{"key":"1188_CR92","doi-asserted-by":"crossref","unstructured":"Yamaguchi K, Poland P, Zhu L, Moghadam-Kia S, Aggarwal R, Maeno T et al. Comparative B cell epitope profiling in Japanese and North American cohorts of MDA5\u2009+\u2009dermatomyositis reveals a direct association between immune repertoire and pulmonary mortality. Rheumatology (Oxford). 2024;keae466.","DOI":"10.1093\/rheumatology\/keae466"},{"issue":"7","key":"1188_CR93","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1093\/rheumatology\/kead550","volume":"63","author":"K Yamaguchi","year":"2024","unstructured":"Yamaguchi K, Poland P, Bijoy George T, Saygin D, Moghadam-Kia S, Aggarwal R, et al. Correlation between B-cell epitope profile and clinical features of anti-MDA5 antibody-positive dermatomyositis. Rheumatology (Oxford). 2024;63(7):2016\u201323.","journal-title":"Rheumatology (Oxford)"},{"key":"1188_CR94","doi-asserted-by":"crossref","unstructured":"Hara R, Watanabe S, Terada N, Kase K, Muto A, Hamaguchi Y et al. The lung as a site for the generation of anti-MDA5 antibody in clinically amyopathic dermatomyositis. Rheumatology (Oxford). 2024;keae314.","DOI":"10.1093\/rheumatology\/keae314"},{"issue":"9","key":"1188_CR95","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1038\/s41409-022-01730-6","volume":"57","author":"M Tamaki","year":"2022","unstructured":"Tamaki M, Matsumi S, Nakasone H, Nakamura Y, Kawamura M, Kawamura S, et al. Interstitial lung disease with anti-melanoma differentiation-associated gene 5 antibody after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transpl. 2022;57(9):1382\u20138.","journal-title":"Bone Marrow Transpl"},{"issue":"11","key":"1188_CR96","doi-asserted-by":"publisher","first-page":"e31727","DOI":"10.1016\/j.heliyon.2024.e31727","volume":"10","author":"M Okamoto","year":"2024","unstructured":"Okamoto M, Zaizen Y, Kaieda S, Nouno T, Koga T, Matama G, et al. Soluble form of the MDA5 protein in human Sera. Heliyon. 2024;10(11):e31727.","journal-title":"Heliyon"},{"issue":"3","key":"1188_CR97","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1002\/art.41105","volume":"72","author":"H Tsuji","year":"2020","unstructured":"Tsuji H, Nakashima R, Hosono Y, Imura Y, Yagita M, Yoshifuji H, et al. Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with High-Dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by Anti-Melanoma Differentiation-Associated gene 5-Positive dermatomyositis. Arthritis Rheumatol. 2020;72(3):488\u201398.","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"1188_CR98","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/resp.13978","volume":"26","author":"T Fujisawa","year":"2021","unstructured":"Fujisawa T, Hozumi H, Kamiya Y, Kaida Y, Akamatsu T, Kusagaya H, et al. Prednisolone and tacrolimus versus prednisolone and cyclosporin A to treat polymyositis\/dermatomyositis-associated ILD: A randomized, open-label trial. Respirology. 2021;26(4):370\u20137.","journal-title":"Respirology"},{"key":"1188_CR99","doi-asserted-by":"crossref","unstructured":"Tian X, Liu L, Liu S, Yang J. Tacrolimus personalized therapy based on CYP3A5 genotype in Chinese patients with idiopathic inflammatory myopathies. Rheumatology (Oxford). 2024;keae316.","DOI":"10.1093\/rheumatology\/keae316"},{"issue":"14","key":"1188_CR100","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1056\/NEJMoa2117912","volume":"387","author":"R Aggarwal","year":"2022","unstructured":"Aggarwal R, Charles-Schoeman C, Schessl J, Bata-Cs\u00f6rg\u0151 Z, Dimachkie MM, Griger Z, et al. Trial of intravenous immune Globulin in dermatomyositis. N Engl J Med. 2022;387(14):1264\u201378.","journal-title":"N Engl J Med"},{"issue":"9","key":"1188_CR101","doi-asserted-by":"publisher","first-page":"3704","DOI":"10.1093\/rheumatology\/keab928","volume":"61","author":"LM Wang","year":"2022","unstructured":"Wang LM, Yang QH, Zhang L, Liu SY, Zhang PP, Zhang X, et al. Intravenous Immunoglobulin for interstitial lung diseases of anti-melanoma differentiation-associated gene 5-positive dermatomyositis. Rheumatology (Oxford). 2022;61(9):3704\u201310.","journal-title":"Rheumatology (Oxford)"},{"key":"1188_CR102","doi-asserted-by":"publisher","first-page":"102941","DOI":"10.1016\/j.jaut.2022.102941","volume":"133","author":"P Bay","year":"2022","unstructured":"Bay P, de Chambrun MP, Rothstein V, Mahevas M, De Prost N, Roux A, et al. Efficacy of plasma exchange in patients with anti-MDA5 rapidly progressive interstitial lung disease. J Autoimmun. 2022;133:102941.","journal-title":"J Autoimmun"},{"issue":"1","key":"1188_CR103","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/jca.21833","volume":"36","author":"T Saito","year":"2021","unstructured":"Saito T, Mizobuchi M, Miwa Y, Sugiyama M, Mima Y, Iida A, et al. Anti-MDA-5 antibody-positive clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease treated with therapeutic plasma exchange: A case series. J Clin Apher. 2021;36(1):196\u2013205.","journal-title":"J Clin Apher"},{"issue":"1","key":"1188_CR104","doi-asserted-by":"publisher","first-page":"2411605","DOI":"10.1080\/07853890.2024.2411605","volume":"56","author":"Y Yang","year":"2024","unstructured":"Yang Y, Yang YT, Huo RX, Meng DL, Huang XX, Lin JY. Short-term efficiency of plasma exchange in combination with immunosuppressants and\/or biologics in the treatment of idiopathic inflammatory myopathy with rapidly progressive interstitial lung disease: a systematic review and meta-analysis. Ann Med. 2024;56(1):2411605.","journal-title":"Ann Med"},{"issue":"2","key":"1188_CR105","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s10067-022-06403-9","volume":"42","author":"J Li","year":"2023","unstructured":"Li J, Wang S, Zheng J, Li Q, Li J, Lu L. Clinical characteristics of and risk factors for Pneumocystis jirovecii pneumonia in anti-melanoma differentiation-associated gene 5 (Anti-MDA5) antibody-positive dermatomyositis patients: a single-center retrospective study. Clin Rheumatol. 2023;42(2):453\u201362.","journal-title":"Clin Rheumatol"},{"issue":"10","key":"1188_CR106","doi-asserted-by":"publisher","first-page":"3302","DOI":"10.1093\/rheumatology\/kead063","volume":"62","author":"X Chen","year":"2023","unstructured":"Chen X, Shu X, He L, Yang H, Lu X, Wang G, et al. High prevalence and mortality of Pneumocystis jirovecii pneumonia in anti-MDA5 antibody-positive dermatomyositis. Rheumatology (Oxford). 2023;62(10):3302\u20139.","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"1188_CR107","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1093\/rheumatology\/kead034","volume":"62","author":"L Liu","year":"2023","unstructured":"Liu L, Zhang Y, Liu S, Wang C, Zhang L, Guan W, et al. Compounded sulfamethoxazole improved the prognosis of dermatomyositis patients positive with anti-melanoma differentiation-associated gene 5. Rheumatology (Oxford). 2023;62(9):3095\u2013100.","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"1188_CR108","doi-asserted-by":"publisher","first-page":"e00235","DOI":"10.1002\/rcr2.235","volume":"5","author":"M Hayashi","year":"2017","unstructured":"Hayashi M, Aoki A, Asakawa K, Sakagami T, Kikuchi T, Takada T. Cytokine profiles of amyopathic dermatomyositis with interstitial lung diseases treated with mycophenolate. Respirol Case Rep. 2017;5(4):e00235.","journal-title":"Respirol Case Rep"},{"issue":"4","key":"1188_CR109","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.semarthrit.2020.03.007","volume":"50","author":"F Romero-Bueno","year":"2020","unstructured":"Romero-Bueno F, Diaz Del Campo P, Trallero-Aragu\u00e1s E, Ruiz-Rodr\u00edguez JC, Castellvi I, Rodriguez-Nieto MJ, et al. Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease. Semin Arthritis Rheum. 2020;50(4):776\u201390.","journal-title":"Semin Arthritis Rheum"},{"issue":"7","key":"1188_CR110","doi-asserted-by":"publisher","first-page":"e227","DOI":"10.1093\/rheumatology\/keaa906","volume":"60","author":"X Zhang","year":"2021","unstructured":"Zhang X, Zhou S, Wu C, Li M, Wang Q, Zhao Y, et al. Tocilizumab for refractory rapidly progressive interstitial lung disease related to anti-MDA5-positive dermatomyositis. Rheumatology (Oxford). 2021;60(7):e227\u20138.","journal-title":"Rheumatology (Oxford)"},{"key":"1188_CR111","doi-asserted-by":"publisher","first-page":"1497168","DOI":"10.3389\/fped.2024.1497168","volume":"12","author":"L Qiu","year":"2024","unstructured":"Qiu L, Shao X, Ma L, Fan Z, Yu H. Successful Tocilizumab treatment for rapidly progressive interstitial lung disease with anti-MDA5-positive juvenile dermatomyositis: a case report and literature review. Front Pediatr. 2024;12:1497168.","journal-title":"Front Pediatr"},{"key":"1188_CR112","doi-asserted-by":"crossref","unstructured":"Zheng Q, Wang Z, Tan Y, Zhu K, Lu M. Over activation of IL-6\/STAT3 signaling pathway in juvenile dermatomyositis. Rheumatol Ther. 2024.","DOI":"10.1007\/s40744-024-00699-6"},{"issue":"1","key":"1188_CR113","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s13075-024-03415-5","volume":"26","author":"Y Niu","year":"2024","unstructured":"Niu Y, Liu S, Qiu Q, Fu D, Xiao Y, Liang L, et al. Increased serum level of IL-6 predicts poor prognosis in anti-MDA5-positive dermatomyositis with rapidly progressive interstitial lung disease. Arthritis Res Ther. 2024;26(1):184.","journal-title":"Arthritis Res Ther"},{"issue":"27","key":"1188_CR114","doi-asserted-by":"publisher","first-page":"8725","DOI":"10.1021\/bi0202023","volume":"41","author":"T Habib","year":"2002","unstructured":"Habib T, Senadheera S, Weinberg K, Kaushansky K. The common gamma chain (gamma c) is a required signaling component of the IL-21 receptor and supports IL-21-induced cell proliferation via JAK3. Biochemistry. 2002;41(27):8725\u201331.","journal-title":"Biochemistry"},{"issue":"1","key":"1188_CR115","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4049\/jimmunol.167.1.1","volume":"167","author":"H Asao","year":"2001","unstructured":"Asao H, Okuyama C, Kumaki S, Ishii N, Tsuchiya S, Foster D, et al. Cutting edge: the common gamma-chain is an indispensable subunit of the IL-21 receptor complex. J Immunol. 2001;167(1):1\u20135.","journal-title":"J Immunol"},{"key":"1188_CR116","doi-asserted-by":"publisher","first-page":"175346662412940","DOI":"10.1177\/17534666241294000","volume":"18","author":"Y Wang","year":"2024","unstructured":"Wang Y, Zou R, Wei J, Tang C, Wang J, Lin M. The efficacy and safety of Tofacitinib in anti-melanoma differentiation-associated gene 5 antibody positive dermatomyositis associated interstitial lung disease: a systematic review and meta-analysis. Ther Adv Respir Dis. 2024;18:17534666241294000.","journal-title":"Ther Adv Respir Dis"},{"issue":"3","key":"1188_CR117","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1056\/NEJMc1900045","volume":"381","author":"Z Chen","year":"2019","unstructured":"Chen Z, Wang X, Ye S. Tofacitinib in amyopathic Dermatomyositis-Associated interstitial lung disease. N Engl J Med. 2019;381(3):291\u20133.","journal-title":"N Engl J Med"},{"issue":"1","key":"1188_CR118","doi-asserted-by":"publisher","first-page":"e002795","DOI":"10.1136\/rmdopen-2022-002795","volume":"9","author":"T Ida","year":"2023","unstructured":"Ida T, Furuta S, Takayama A, Tamura J, Hayashi Y, Abe K, et al. Efficacy and safety of dose escalation of Tofacitinib in refractory anti-MDA5 antibody-positive dermatomyositis. RMD Open. 2023;9(1):e002795.","journal-title":"RMD Open"},{"issue":"1","key":"1188_CR119","doi-asserted-by":"publisher","first-page":"2391445","DOI":"10.1080\/09546634.2024.2391445","volume":"35","author":"X Huang","year":"2024","unstructured":"Huang X, Zhang G, Luo S. A case of refractory anti-MDA5-positive amyopathic dermatomyositis successfully treated with Upadacitinib. J Dermatolog Treat. 2024;35(1):2391445.","journal-title":"J Dermatolog Treat"},{"issue":"5","key":"1188_CR120","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s00296-024-05551-2","volume":"44","author":"H Harada","year":"2024","unstructured":"Harada H, Shoda H, Tsuchiya H, Misaki M, Sawada T, Fujio K. Baricitinib for anti-melanoma differentiation-associated protein 5 antibody-positive dermatomyositis-associated interstitial lung disease: a case series and literature review on Janus kinase inhibitors for the disease. Rheumatol Int. 2024;44(5):961\u201371.","journal-title":"Rheumatol Int"},{"issue":"6","key":"1188_CR121","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1007\/s10067-020-05530-5","volume":"40","author":"Y Ge","year":"2021","unstructured":"Ge Y, Li S, Tian X, He L, Lu X, Wang G. Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis responds to rituximab therapy. Clin Rheumatol. 2021;40(6):2311\u20137.","journal-title":"Clin Rheumatol"},{"issue":"4","key":"1188_CR122","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1159\/000346573","volume":"225","author":"A Clottu","year":"2012","unstructured":"Clottu A, Laffitte E, Prins C, Chizzolini C. Response of mucocutaneous lesions to rituximab in a case of melanoma differentiation antigen 5-related dermatomyositis. Dermatology. 2012;225(4):376\u201380.","journal-title":"Dermatology"},{"issue":"3","key":"1188_CR123","doi-asserted-by":"publisher","first-page":"536","DOI":"10.3109\/14397595.2015.1014140","volume":"27","author":"Y Koichi","year":"2017","unstructured":"Koichi Y, Aya Y, Megumi U, Shunichi K, Masafumi S, Hiroaki M, et al. A case of anti-MDA5-positive rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis ameliorated by rituximab, in addition to standard immunosuppressive treatment. Mod Rheumatol. 2017;27(3):536\u201340.","journal-title":"Mod Rheumatol"},{"key":"1188_CR124","doi-asserted-by":"publisher","first-page":"105983","DOI":"10.1016\/j.rmed.2020.105983","volume":"172","author":"MM Mao","year":"2020","unstructured":"Mao MM, Xia S, Guo BP, Qian WP, Zheng ZX, Peng XM, et al. Ultra-low dose rituximab as add-on therapy in anti-MDA5-positive patients with polymyositis \/dermatomyositis associated ILD. Respir Med. 2020;172:105983.","journal-title":"Respir Med"},{"issue":"1","key":"1188_CR125","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.chest.2022.08.2209","volume":"163","author":"MT Holzer","year":"2023","unstructured":"Holzer MT, Nies JF, Oqueka T, Huber TB, K\u00f6tter I, Krusche M. Successful rescue therapy with daratumumab in rapidly progressive interstitial lung disease caused by MDA5-Positive dermatomyositis. Chest. 2023;163(1):e1\u20135.","journal-title":"Chest"},{"issue":"3","key":"1188_CR126","doi-asserted-by":"publisher","first-page":"e003238","DOI":"10.1136\/rmdopen-2023-003238","volume":"9","author":"L Ostendorf","year":"2023","unstructured":"Ostendorf L, Muench F, Thorm\u00e4hlen L, Galbav\u00fd Z, K\u00f6rner R, Nee J, et al. Rescue combination treatment of anti-MDA5-associated ARDS with daratumumab. RMD Open. 2023;9(3):e003238.","journal-title":"RMD Open"},{"issue":"2","key":"1188_CR127","first-page":"460","volume":"42","author":"CG Chua","year":"2024","unstructured":"Chua CG, Chai GT, Lim XR, Manghani M, Leung BPL, Koh LW. Successful rescue treatment of refractory anti-MDA5 autoantibody positive dermatomyositis with rapidly progressive interstitial lung disease using daratumumab. Clin Exp Rheumatol. 2024;42(2):460\u20131.","journal-title":"Clin Exp Rheumatol"},{"key":"1188_CR128","doi-asserted-by":"publisher","first-page":"1455944","DOI":"10.3389\/fimmu.2024.1455944","volume":"15","author":"Y Guo","year":"2024","unstructured":"Guo Y, Liu H, Chen B, Zhang K, Meng L, Yan L, et al. Dysregulated CD38 expression on T cells was associated with rapidly progressive interstitial lung disease in anti-melanoma differentiation-associated gene 5 positive dermatomyositis. Front Immunol. 2024;15:1455944.","journal-title":"Front Immunol"},{"issue":"8","key":"1188_CR129","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1136\/annrheumdis-2014-205278","volume":"73","author":"J Zou","year":"2014","unstructured":"Zou J, Li T, Huang X, Chen S, Guo Q, Bao C. Basiliximab May improve the survival rate of rapidly progressive interstitial pneumonia in patients with clinically amyopathic dermatomyositis with anti-MDA5 antibody. Ann Rheum Dis. 2014;73(8):1591\u20133.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"1188_CR130","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1056\/NEJMc2408786","volume":"391","author":"M Hagen","year":"2024","unstructured":"Hagen M, Bucci L, B\u00f6ltz S, N\u00f6thling DM, Rothe T, Anoshkin K, et al. BCMA-Targeted T-Cell-Engager therapy for autoimmune disease. N Engl J Med. 2024;391(9):867\u20139.","journal-title":"N Engl J Med"},{"key":"1188_CR131","doi-asserted-by":"crossref","unstructured":"Bando T, Yamano Y, Takei R, Sasano H, Fukihara J, Yokoyama T et al. Early intervention of antifibrotics along with anti-inflammatory treatment in rapidly progressive interstitial lung disease (RP-ILD) with anti-MDA5 antibody-positive dermatomyositis (MDA5-DM). European Respiratory Journal [Internet]. 2023 Sep 9 [cited 2024 Jan 30];62(suppl 67). Available from: https:\/\/erj.ersjournals.com\/content\/62\/suppl_67\/PA401","DOI":"10.1183\/13993003.congress-2023.PA401"},{"key":"1188_CR132","first-page":"102072","volume":"51","author":"RM Puthumana","year":"2024","unstructured":"Puthumana RM, Koch AL, Schettino C, Vehar SJ. Asymptomatic and slowly progressive anti-MDA5 ILD: A report of three cases deviating from a notoriously rapidly progressive ILD. Respir Med Case Rep. 2024;51:102072.","journal-title":"Respir Med Case Rep"},{"issue":"3","key":"1188_CR133","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s10067-022-06422-6","volume":"42","author":"QY Lian","year":"2023","unstructured":"Lian QY, Chen A, Zhang JH, Xu X, Huang DX, Luo Q, et al. Lung transplantation for anti-MDA5-positive dermatomyositis-associated rapid progressive interstitial lung disease: report of two cases and review of the literature. Clin Rheumatol. 2023;42(3):941\u20137.","journal-title":"Clin Rheumatol"},{"issue":"1","key":"1188_CR134","doi-asserted-by":"publisher","first-page":"e70","DOI":"10.1212\/WNL.0000000000009727","volume":"95","author":"Y Allenbach","year":"2020","unstructured":"Allenbach Y, Uzunhan Y, Toquet S, Leroux G, Gallay L, Marquet A, et al. Different phenotypes in dermatomyositis associated with anti-MDA5 antibody: study of 121 cases. Neurology. 2020;95(1):e70\u20138.","journal-title":"Neurology"},{"issue":"4","key":"1188_CR135","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1002\/art.42308","volume":"75","author":"L Xu","year":"2023","unstructured":"Xu L, You H, Wang L, Lv C, Yuan F, Li J, et al. Identification of three different phenotypes in Anti-Melanoma differentiation-Associated gene 5 Antibody-Positive dermatomyositis patients: implications for prediction of rapidly progressive interstitial lung disease. Arthritis Rheumatol. 2023;75(4):609\u201319.","journal-title":"Arthritis Rheumatol"},{"key":"1188_CR136","doi-asserted-by":"publisher","first-page":"1349611","DOI":"10.3389\/fimmu.2024.1349611","volume":"15","author":"R Guo","year":"2024","unstructured":"Guo R, Yang Y, Gu L, Li X, Ma Y, Liu X, et al. Disease-associated immune cell endotypes in anti-MDA5-positive dermatomyositis using unbiased hierarchical clustering. Front Immunol. 2024;15:1349611.","journal-title":"Front Immunol"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-025-01188-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11926-025-01188-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-025-01188-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T19:04:11Z","timestamp":1770750251000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11926-025-01188-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,5]]},"references-count":136,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1188"],"URL":"https:\/\/doi.org\/10.1007\/s11926-025-01188-7","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,5]]},"assertion":[{"value":"11 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights Statement"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"23"}}